Building on its leadership in point-of-care diagnostic testing,QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a leading global provider of innovative in vitro diagnostic technologies, is expanding its QUICKVUE portfolio with the QUICKVUE Influenza + SARS Test, a CLIA-waived, 510(k)-cleared rapid, easy-to-use immunoassay designed for professional use in physician office laboratories, urgent care centers, emergency departments, pharmacies and decentralized hospital labs.
https://mma.prnewswire.com/media/2777664/QUICKVUE_Influenza_SARS_Test.jpg
The QUICKVUE Influenza + SARS Test is designed to deliverrapid, simultaneous detection and differentiation of influenza A, influenza B and SARS-CoV-2 antigensfrom a single patient sample, providing results in as fast as10 minutes. This capability can help clinicians distinguish between COVID-19 and seasonal flu infections, which present similar symptoms, enabling timely treatment decisions and improved patient outcomes.
Key Features and Benefits:
— Triple Detection Capability: Differentiates influenza A/B and COVID-19 in one test.
— Fast Results: Clear results available in as fast as 10 minutes at the point of care.
— Professional Use: Designed for CLIA-waived and moderate/high-complexity lab settings.
— Efficient Workflow: Easy-to-collect nasal swab, streamlined processing and clear result window.
— Affordable Access: Cost-effective visual combo test.
“Physician office labs and urgent care centers are on the front lines of respiratory illness diagnosis. With theQUICKVUE Influenza + SARS Test, we're equipping healthcare providers with a reliable, affordable and efficient tool to differentiate between COVID-19 and influenza in minutes,” said Tammi Ranalli, PhD, Senior Vice President, Molecular Diagnostics and Point of Care Business Units, QuidelOrtho. “This innovation reflectsQuidelOrtho's commitment to supporting healthcare professionals with cost-effective solutions that streamline clinical decisions and help manage seasonal surges in respiratory infections.”
The launch of the QUICKVUE Influenza + SARS Test expands QuidelOrtho's portfolio of respiratory solutions, including the SOFIA™ 2 Flu + SARS Antigen FIA, by offering a visually read option alongside QuidelOrtho's instrumented version and reinforces QuidelOrtho's market leadership in point-of-care respiratory testing. The QUICKVUE Influenza + SARS Test isavailablein the United States through QuidelOrtho's existing distribution channels and is not intended for in-home use.
About QuidelOrtho CorporationWith expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, delivering fast, accurate and reliable results that help improve patient outcomes – from the point of care to hospital, lab to clinic. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.
For more information, visitwww.quidelortho.comand follow QuidelOrtho on LinkedIn, Facebook and X.
Investor Contact:Juliet CunninghamVice President, Investor RelationsIR@QuidelOrtho.com
Media Contact:D. Nikki WheelerSenior Director, Corporate Communicationsmedia@QuidelOrtho.com
https://mma.prnewswire.com/media/2724032/QuidelOrtho_Corporation_Logo.jpg
https://edge.prnewswire.com/c/img/favicon.png?sn=LA78153&sd=2025-09-22
View original content to download multimedia:https://www.prnewswire.com/news-releases/quidelortho-announces-availability-of-quickvue-influenza–sars-test-for-professional-use-302561981.html
SOURCE QuidelOrtho Corporation
https://rt.newswire.ca/rt.gif?NewsItemId=LA78153&Transmission_Id=202509220700PR_NEWS_USPR_____LA78153&DateId=20250922